Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...

Novo Nordisk said on Monday it would lower the U.S. price of its injectable Wegovy obesity drug and pledged to go "all in" on its upcoming oral weight-loss pill, as the firm races to claw back lost ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

The long-term side effects of Wegovy® may include problems with your pancreas, kidneys, or gallbladder. These side effects are rare. For many, Wegovy® is safe to use long-term, and the benefits ...

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform. The discussions are about both ...

Novo Nordisk announced on Monday that it is lowering costs for weight loss and diabetes drugs, weeks after it struck a deal ...

Oral weight-loss pills will be replacing GLP-1 shots by March 2026, Medicare and Medicaid Services Administrator Dr. Mehmet Oz predicted on Monday. Oz made the statement during a Monday morning ...

The surge in usage of 'GLP-1'-style weight loss medications is seeing a "ripple effect" begin to unfold, impacting eating patterns in a number of ...

His secret, he said, is a weekly injection of retatrutide, a next-generation weight-loss drug. Also known as “triple G”, the ...

People buying the peptide retatrutide online could suffer from side-effects ranging from nausea to pancreatitis ...

The announcement comes as the Danish drugmaker struggles to grab significant market share in the Indian market before it ...